Oridonin attenuates atherosclerosis by inhibiting foam macrophage formation and inflammation through FABP4/PPARγ signalling
Journal of Cellular and Molecular Medicine · 2023-12 · 27 (24) · 4155-4170
DOI: 10.1111/jcmm.18000 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, online erschienen am 31.10.2023. Verfasst von Ming Zhang und 10 weiteren Autor:innen. Beteiligte Einrichtung: The Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People's Hospital, Qingyuan, China. Hauptthemen laut MEDLINE: PPAR gamma, Atherosclerosis. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Guangdong Province.
Abstract (Originalsprache)
Both lipid accumulation and inflammatory response in lesion macrophages fuel the progression of atherosclerosis, leading to high mortality of cardiovascular disease. A therapeutic strategy concurrently targeting these two risk factors is promising, but still scarce. Oridonin, the bioactive medicinal compound, is known to protect against inflammatory response and lipid dysfunction. However, its effect on atherosclerosis and the underlying molecular mechanism remain elusive. Here, we showed that oridonin attenuated atherosclerosis in hyperlipidemic ApoE knockout mice. Meanwhile, we confirmed the protective effect of oridonin on the oxidized low‐density lipoprotein (oxLDL)‐induced foam macrophage formation, resulting from increased cholesterol efflux, as well as reduced inflammatory response. Mechanistically, the network pharmacology prediction and further experiments revealed that oridonin dramatically facilitated the expression of peroxisome proliferator‐activated receptor gamma (PPARγ), thereby regulating liver X receptor‐alpha (LXRα)‐induced ATP‐binding cassette transporter A1 (ABCA1) expression and nuclear factor NF‐kappa‐B (NF‐κB) translocation. Antagonist of PPARγ reversed the cholesterol accumulation and inflammatory response mediated by oridonin. Besides, RNA sequencing analysis revealed that fatty acid binding protein 4 (FABP4) was altered responding to lipid modulation effect of oridonin. Overexpression of FABP4 inhibited PPARγ activation and blunted the benefit effect of oridonin on foam macrophages. Taken together, oridonin might have potential to protect against atherosclerosis by modulating the formation and inflammatory response in foam macrophages through FABP4/PPARγ signalling.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People's Hospital, Qingyuan, China.
- Hengyang Medical School, University of South China, Hengyang, China.
- Guilin Medical University, Guilin, China.
- Xiangya Hospital, Central South University, Changsha, China.
ORCID-Profile: Ming Zhang, Lianjie Hou, Guojun Zhao
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Guangdong Province
Zitieren
APA
Zhang, M., Hou, L., Tang, W., Lei, W., Lin, H., Wang, Y., Long, H., Lin, S., Chen, Z., Wang, G., & Zhao, G. (2023). Oridonin attenuates atherosclerosis by inhibiting foam macrophage formation and inflammation through FABP4/PPARγ signalling. Journal of Cellular and Molecular Medicine, 27(24), 4155-4170. https://doi.org/10.1111/jcmm.18000
Vancouver
Zhang M, Hou L, Tang W, Lei W, Lin H, Wang Y, et al. Oridonin attenuates atherosclerosis by inhibiting foam macrophage formation and inflammation through FABP4/PPARγ signalling. Journal of Cellular and Molecular Medicine. 2023;27(24):4155-4170. doi:10.1111/jcmm.18000
BibTeX
@article{Zhang2023,
author = {Zhang, Ming and Hou, Lianjie and Tang, Wanying and Lei, Weixing and Lin, Huiling and Wang, Yu and Long, Haijiao and Lin, Shuyun and Chen, Zhi and Wang, Guangliang and Zhao, Guojun},
title = {Oridonin attenuates atherosclerosis by inhibiting foam macrophage formation and inflammation through FABP4/PPARγ signalling},
journal = {Journal of Cellular and Molecular Medicine},
year = {2023},
volume = {27},
number = {24},
pages = {4155--4170},
doi = {10.1111/jcmm.18000}
}
EUVIMED